ONCOARENDI THERAPEUTICS LLC
Madison, CT · Biotech · Public
Oral small molecule chitotriosidase (CHIT) inhibitor for sarcoidosis
- Grants
- $4.0M
- 7 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma | $225,000 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma | $1,505,420 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Development of an Oral Acidic Mammalian Chitinase Inhibitor to Treat Asthma | $1,505,420 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Potent oral chitotriosidase-1 inhibitors as a novel therapy for sarcoidosis | $237,200 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Potent oral chitotriosidase-1 inhibitors as a novel therapy for sarcoidosis | $237,200 | |
| Federal grant | Department of Health and Human Services · Phase I · Myocardin-related transcription factor (MRTF) pathway modulators as a novel, disease-modifying oral medicine for idiopathic pulmonary fibrosis (IPF) | $241,125 | |
| Federal grant | Department of Health and Human Services · Phase I · Myocardin-related transcription factor (MRTF) pathway modulators as a novel, disease-modifying oral medicine for idiopathic pulmonary fibrosis (IPF) | $66,458 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2906 | Tubulis | — | — |
| 2907 | Lyric Therapeutics | — | — |
| 2908 | Beacon Therapeutics | — | — |
| 2909 | ONCOARENDI THERAPEUTICS LLC | — | — |
| 2910 | MEDCHEM PARTNERS LLC | — | — |
| 2911 | Percev LLC | — | — |
| 2912 | Aiolos Bio | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.